Nationwide Fund Advisors raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 27.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 168,709 shares of the biopharmaceutical company’s stock after acquiring an additional 36,764 shares during the quarter. Nationwide Fund Advisors owned approximately 0.12% of Amicus Therapeutics worth $1,699,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of FOLD. Wellington Management Group LLP lifted its holdings in shares of Amicus Therapeutics by 358.4% in the first quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock worth $38,083,000 after acquiring an additional 4,175,995 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after acquiring an additional 3,055,039 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Amicus Therapeutics in the first quarter worth about $21,394,000. Palo Alto Investors LLC lifted its holdings in shares of Amicus Therapeutics by 23.0% in the first quarter. Palo Alto Investors LLC now owns 7,882,988 shares of the biopharmaceutical company’s stock worth $56,206,000 after acquiring an additional 1,472,958 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics by 4.2% in the first quarter. Vanguard Group Inc. now owns 8,687,760 shares of the biopharmaceutical company’s stock worth $61,944,000 after acquiring an additional 353,949 shares during the last quarter.
In related news, SVP Daphne Quimi sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $99,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John F. Crowley sold 449,295 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $14.33, for a total value of $6,438,397.35. Following the transaction, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,455,760.59. The disclosure for this sale can be found here. Insiders sold 628,224 shares of company stock valued at $9,024,003 in the last quarter. Corporate insiders own 3.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/27/nationwide-fund-advisors-buys-36764-shares-of-amicus-therapeutics-inc-fold.html.
Amicus Therapeutics, Inc. (FOLD) opened at 13.45 on Friday. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.60. The firm’s 50-day moving average is $14.35 and its 200 day moving average is $11.26. The company’s market cap is $2.21 billion.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The firm had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. On average, equities analysts expect that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current fiscal year.
FOLD has been the subject of a number of research reports. Robert W. Baird reissued an “outperform” rating and issued a $12.00 target price on shares of Amicus Therapeutics in a report on Friday, June 30th. Cowen and Company reiterated a “buy” rating and issued a $16.00 price objective (up previously from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. BidaskClub upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of Amicus Therapeutics in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $17.81.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.